CymaBay Therapeutics Inc (NASDAQ:CBAY)

North American company
add to virtual portfolio
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - CBAY

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - CBAY

  • Market Cap$419.520m
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINUS23257D1037

Company Profile

CymaBay Therapeutics Inc is a part of the healthcare sector based in the United States. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta.CymaBay Therapeutics Inc is an American biotechnology enterprise. Its product candidates include Arhalofenate, MBX-8025, and MBX-2982, which are meant to combat serious metabolic diseases.

Latest CBAY news

Currently there for this company. Visit our news hub for other news .